Clinical Research in Cardiology

, Volume 99, Issue 9, pp 553–556

Standard PAH therapy improves long term survival in CTEPH patients

  • Hans-Juergen Seyfarth
  • Michael Halank
  • Heinrike Wilkens
  • Hans-Joachim Schäfers
  • Ralf Ewert
  • Martin Riedel
  • Ernst Schuster
  • Hans Pankau
  • Stefan Hammerschmidt
  • Hubert Wirtz
Original Paper

DOI: 10.1007/s00392-010-0156-4

Cite this article as:
Seyfarth, HJ., Halank, M., Wilkens, H. et al. Clin Res Cardiol (2010) 99: 553. doi:10.1007/s00392-010-0156-4

Abstract

Background

Chronic thromboembolic pulmonary hypertension (CTEPH), subsequent to pulmonary embolism is a relatively frequent cause of pulmonary hypertension. Similar to patients with pulmonary arterial hypertension (PAH), CTEPH carries a poor prognosis. There is no hard evidence for any other therapy except pulmonary endarterectomy and none for those patients that are not eligible for this procedure.

Patients and methods

Fifty patients with confirmed, inoperable CTEPH receiving specific vasodilative therapy (prostanoids, endothelin receptor antagonists, PDE 5-inhibitors or combination) were included in this retrospective study (mean age 55 years, range 16–76 years; 36 female, 14 male). Kaplan–Meier plots of these patients were compared with Kaplan–Meier plots of two historical CTEPH patient groups without any specific vasodilative treatment by log rank tests.

Results

CTEPH patients treated with specific vasodilative compounds as used for therapy of PAH were followed up for 52 ± 30 months and had a significantly improved survival compared with patients treated without PAH type vasodilators (p ≤ 0.0002).

Conclusion

Our data may generate the hypothesis that specific vasodilative treatment improves outcome in patients with inoperable CTEPH.

Keywords

Pulmonary hypertension Pulmonary embolism Survival Vasodilator agents 

Abbreviations

CI

Cardiac index

CTEPH

Chronic thromboembolic pulmonary hypertension

IPAH

Idiopathic pulmonary arterial hypertension

mPAP

Mean pulmonary arterial pressure

PAH

Pulmonary arterial hypertension

PEA

Pulmonary endarterectomy

PVR

Pulmonary vascular resistance

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Hans-Juergen Seyfarth
    • 1
  • Michael Halank
    • 2
  • Heinrike Wilkens
    • 3
  • Hans-Joachim Schäfers
    • 3
  • Ralf Ewert
    • 4
  • Martin Riedel
    • 5
  • Ernst Schuster
    • 6
  • Hans Pankau
    • 1
  • Stefan Hammerschmidt
    • 1
  • Hubert Wirtz
    • 1
  1. 1.Department of Respiratory MedicineUniversity of LeipzigLeipzigGermany
  2. 2.Internal Medicine IUniversity of DresdenDresdenGermany
  3. 3.Universitätsklinikum Homburg/SaarHomburgGermany
  4. 4.University of GreifswaldGreifswaldGermany
  5. 5.Deutsches Herzzentrum, Klinikum Der TU MünchenMunichGermany
  6. 6.Institut for Medical Informatics, Statistics and EpidemiologyUniversity of LeipzigLeipzigGermany

Personalised recommendations